Avacincaptad pegol (ACP)
Pre-clinicalRecruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Geographic Atrophy
Conditions
Geographic Atrophy, Macular Degeneration
Trial Timeline
Jan 22, 2025 → Jan 31, 2030
NCT ID
NCT06779773About Avacincaptad pegol (ACP)
Avacincaptad pegol (ACP) is a pre-clinical stage product being developed by Astellas Pharma for Geographic Atrophy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06779773. Target conditions include Geographic Atrophy, Macular Degeneration.
What happened to similar drugs?
1 of 12 similar drugs in Geographic Atrophy were approved
Approved (1) Terminated (3) Active (8)
Hype Score Breakdown
Clinical
3
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06779773 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Geographic Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| avacincaptad pegol | Astellas Pharma | Phase 3 | 40 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2/3 | 38 |
| avacincaptad pegol | Astellas Pharma | Approved | 50 |
| Avacincaptad Pegol + Sham | Astellas Pharma | Phase 3 | 40 |
| ABBV-6628 + SYFOVRE | AbbVie | Phase 1/2 | 39 |
| FWY003 + Placebo | Novartis | Phase 2 | 42 |
| CLG561 + LFG316 + Sham injection | Novartis | Phase 2 | 35 |
| LFG316 + Sham + LFG316 Lower dose | Novartis | Phase 2 | 35 |
| Lampalizumab | Roche | Phase 3 | 32 |
| Lampalizumab | Roche | Phase 3 | 32 |
| Lampalizumab | Roche | Phase 3 | 32 |
| RO7669330 + Syfovre™ + Izervay™ | Roche | Phase 1 | 36 |
| RO7303359 | Roche | Phase 1 | 29 |
| SAR446597 + Sham Comparator | Sanofi | Phase 1/2 | 39 |
| Pozelimab | Regeneron Pharmaceuticals | Phase 1 | 36 |
| IONIS-FB-Lrx + Placebo (sterline saline 0.9%) | Ionis Pharmaceuticals | Phase 2 | 24 |
| Tinlarebant + Placebo | Belite Bio | Phase 3 | 41 |
| Pegcetacoplan | Apellis Pharmaceuticals | Pre-clinical | 24 |
| APL-2 + APL-2 | Apellis Pharmaceuticals | Phase 3 | 34 |
| APL-2, Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 34 |